Medication topics
Methotrexate articles covering immunomodulator treatment, monitoring, safety, combination therapy, and IBD care decisions. Access context emphasizes approvals, coverage, affordability, availability, and policy decisions.
3 articles
FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
